29 results
To compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established peripheral artery disease.
Ticagrelor, at steady state (i.e. after 30 days), will be associated to an improved endothelial function as compared to clopidogrel or prasugrel.
The primary objective is to investigate the influence of vigilance state on MEP amplitude in healthy adults. Secondary objectives are to develop a paradigm to stabilize vigilance state resulting in lower MEP amplitude variability in healthy adults…
To study whether ticagrelor, added to acetylsalicylic acid, modulates the inflammatory response to the administration of lipopolysaccharide (LPS) in humans in vivo.
To estimate the bleeding risk with rivaroxaban, compared with ASA, in addition to a singleantiplatelet agent (clopidogrel or ticagrelor), in subjects with a recent ACS .
To evaluate safety of 3-months versus standard 12-months of DAPT
We plan to (1) prove that microTMS can influence brain connectivity in healthy volunteers, and (2) optimize the stimulation parameters. As soon as a considerable effect is obtained, the new project will follow up for patients.
The goal of the current study is to investigate the functional relevance of higher order cortical areas for cognitive task execution involving inhibitory and emotional processes by means of TMS.
The aim of this study is to compare the integrity of the corticospinal tract and cortical reorganization of shoulder girdle muscle representations in chronic stroke patients with and without GHS as well as healthy controls.
Probleemstelling: Er is geen duidelijkheid of rTMS, toegepast binnen het reguliere revalidatieprogramma na een beroerte, leidt tot een extra verbetering in motorische herstel volgens de klinimetrie zoals gehanteerd binnen de in Nederland gebruikte…
Can this effect be utilised clinically, especially in patients with major depressive disorder?
The current study is being conducted to determine whether long-term dual-antiplatelet therapy with ticagrelor in combination with ASA (recommended daily dose 75-100 mg) is beneficial in patients with history of MI (1-3 years ago) and additional risk…
To investigate whether ticagrelor increases adenosine receptor stimulation in humans in vivo by ENT inhibition.
Aims of the Study: Our main aim is to characterize cortical brain plasticity in individuals with impaired fasting glucose (IFG) and patients with type II diabetes mellitus (DM2) as compared with age-, gender-, and IQ-matched healthy controls(HC).•…
To determine if ticagrelor at treatment steady state will be associated to an improved microvascular function as compared to prasugrel in revascularized STEMI patients.
The overall safety objective of this study is to assess the safety and tolerability of long-term therapy with ticagrelor compared to placebo in patients with T2DM at high risk of CV events, with or without background low-dose ASA therapy. Bleeding…
To explore whether influence on parasympathetic activity can be used as a functional outcome measure reflecting adequate targeting of the DLPFC-sgACC network and, secondary: 1) to explore the dose-response to the intensity of the TMS output and 2)…
To investigate whether a combination of ticagrelor 90mg twice daily and ASA 80mg once daily is superior to ASA 80mg once daily alone in the prevention of SVG occlusion in patients who underwent CABG with use of one or more SVGs, as assessed with…
To investigate if antiplatelet therapy consisting of ticagrelor plus ASA is superior to clopidogrel plus ASA in preventing ischaemic brain lesions occurring as a result of CAS assessed on magnetic resonance imaging (MRI).